A5058399030- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Melanoma and MAPK Pathways
- Cutaneous Melanoma Detection and Management
- Immune Cell Function and Interaction
- Health Systems, Economic Evaluations, Quality of Life
- Gut microbiota and health
- Immune cells in cancer
- Cancer survivorship and care
- Colorectal Cancer Treatments and Studies
- Single-cell and spatial transcriptomics
- Genetic factors in colorectal cancer
- Colorectal and Anal Carcinomas
- Brain Metastases and Treatment
- T-cell and B-cell Immunology
- Physical Activity and Health
- Clostridium difficile and Clostridium perfringens research
- Pancreatic and Hepatic Oncology Research
- Chronic Lymphocytic Leukemia Research
- Heparin-Induced Thrombocytopenia and Thrombosis
- Acupuncture Treatment Research Studies
- PARP inhibition in cancer therapy
- Nutrition and Health in Aging
- Mast cells and histamine
Utrecht University
2022-2025
University Medical Center Utrecht
2018-2025
Heidelberg University
2023-2024
University Hospital Heidelberg
2023-2024
Medicines Evaluation Board
2024
Management of checkpoint inhibitor-induced immune-related adverse events (irAEs) is primarily based on expert opinion. Recent studies have suggested detrimental effects anti-tumor necrosis factor checkpoint-inhibitor efficacy.To determine the association toxic effect management with progression-free survival (PFS), overall (OS), and melanoma-specific (MSS) in patients advanced melanoma treated first-line ipilimumab-nivolumab combination therapy.This population-based, multicenter cohort study...
Retrospective studies suggest that immunosuppressive treatment of immune-related adverse events (irAEs) impairs survival in patients with melanoma who received immune checkpoint inhibitors. Here, we study this association across tumor types using data from six international phase II/III registrational trials.
Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs) that range from mild to life-threatening. Age itself does not seem be a predictor for the occurrence of irAEs. It is unknown whether frailty plays role in Therefore, authors assessed irAEs and their sequelae occur more often frail patients than fit according Geriatric 8 (G8) assessment.Patients with melanoma aged 70 years older who were about start ICI therapy screened G8 assessment enrolled this prospective,...
Immune checkpoint inhibitors (ICI) have revolutionized the treatment landscape of advanced malignancies, but come with a diverse spectrum immune-related adverse events (irAEs). Mechanistic studies can aid transition from expert-opinion to evidence-based irAE strategies. We aimed longitudinally characterize peripheral blood T and B cell dynamics in ICI-treated patients by multicolor flow cytometry serum multiplex immunoassay at baseline, ± 3 weeks 6 or upon clinically relevant irAEs. analyzed...
Abstract Background Effectivity of BRAF(/MEK) inhibitor rechallenge has been described in prior studies. However, structured data are largely lacking. Methods Data from all advanced melanoma patients treated with BRAFi(/MEKi) were retrieved the Dutch Melanoma Treatment Registry. The authors analyzed objective response rate (ORR), progression‐free survival (PFS), and overall (OS) for both first treatment rechallenge. They performed a multivariable logistic regression Cox proportional hazards...
Abstract Introduction The association of body composition with checkpoint inhibitor outcomes in melanoma is a matter ongoing debate. In this study, we aim to investigate mass index (BMI) alongside CT-derived metrics the largest cohort date. Methods Patients treated first-line anti-PD1 ± anti-CTLA4 for advanced were retrospectively identified from 11 centers Netherlands. From baseline CT scans, five extracted: subcutaneous adipose tissue index, visceral and skeletal muscle density gauge....
Current knowledge on prognostic biomarkers (especially BRAFV600E /RAS mutations) in metastatic colorectal cancer (mCRC) is mainly based mCRC patients with proficient mismatch repair (pMMR) tumors. It uncertain whether these have the same value deficient (dMMR) This observational cohort study combined a population-based Dutch (2014-2019) and large French multicenter (2007-2017). All histologically proven dMMR tumor were included. In our real-world data of 707 patients, 438 treated first-line...
Abstract Predicting who will benefit from treatment with immune checkpoint inhibition (ICI) in patients advanced melanoma is challenging. We developed a multivariable prediction model for response to ICI, using routinely available clinical data including primary characteristics. used population‐based cohort of 3525 cutaneous treated anti‐PD‐1‐based therapy. Our predicting within 6 months after ICI initiation was internally validated bootstrap resampling. Performance evaluation included...
The intestinal microbiota plays a significant role in maintaining systemic and homeostasis, but can also influence diseases such as inflammatory bowel disease (IBD) cancer. Certain bacterial species within the tract chronically activate immune system, leading to low-grade inflammation. As result, plasma cells produce high levels of secretory antigen-specific immunoglobulin A (IgA), which coats immunostimulatory bacteria. This IgA response against bacteria may be associated with maintenance...
Abstract Background Although animal experiments suggest beneficial effects of physical activity (PA) on antitumor immunity, little is known about the PA immune checkpoint inhibitor (ICI) toxicity and effectiveness in humans. We assessed association with immune-related adverse events (irAE) survival patients undergoing ICI. Methods Patients receiving ICI who completed Dutch short questionnaire to assess health enhancing (SQUASH) at start treatment as part prospective UNICIT study an academic...
Abstract Introduction Hyperprogression, characterized by a rapid acceleration in tumor growth, is novel pattern of progression recently described patients treated with immune checkpoint inhibitors. This study aims to assess the incidence hyperprogression advanced melanoma Methods Clinical and radiological findings all who started inhibitors between January 2013 March 2019 tertiary academic center Netherlands were analyzed. Change burden was calculated assessing volumetric growth using...
BackgroundImmune checkpoint inhibitor (ICI) can cause severe and sometimes fatal immune-related adverse events (irAEs). Since these irAEs mimick immunological disease, a female predominance has been speculated on. Nevertheless, no demographic or tumour-related factors associated with an increased risk of have identified until now.MethodsRisk ratios (grade ≥3) for age, sex, WHO performance status, number comorbidities, stage metastases serum lactate dehydrogenases (LDH) were estimated using...
Abstract Immune checkpoint inhibitors (ICI) have revolutionized the treatment landscape of advanced malignancies, but come with a diverse spectrum immune-related adverse events (irAEs). Mechanistic studies can aid transition from expert-opinion to evidence-based irAE strategies. We aimed longitudinally characterize peripheral blood T and B cell dynamics in ICI-treated patients by multicolor flow cytometry serum multiplex immunoassay at baseline, ±3 weeks ±6 or upon clinically relevant irAEs....
Abstract Introduction The association of body composition with checkpoint inhibitor outcomes in melanoma is a matter ongoing debate. In this study, we aim to add previous evidence by investigating mass index (BMI) alongside CT derived metrics the largest cohort date. Method Patients treated first-line anti-PD1 ± anti-CTLA4 for advanced were retrospectively identified from 11 reference centers Netherlands. Age, sex, Eastern Cooperative Oncology Group performance status, serum lactate...